David Hung Launches Start-Up Nuvation With Old Medivation Team And $275m

The former Medivation CEO, after a brief detour heading up Axovant, is returning to oncology, but the new company is keeping details about the seven cancer drug programs in its pipeline under wraps.

SC1910_Businessman-sketch_150613505_1200.jpg
Start-up Nuvation has seven cancer drug programs but intends to expand its pipeline. • Source: Shutterstock

Former Medivation Inc. CEO David Hung is returning to oncology with the new cancer drug company Nuvation Bio Inc., which has raised $275m in series A venture capital and reassembled members of the team that developed and launched the prostate cancer blockbuster Xtandi (enzalutamide) before selling Medivation to Pfizer Inc. for $14.3bn in 2016.

With offices in New York and San Francisco, Nuvation describes itself as a “stealth biotechnology company” as it keeps the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.